Mint Tea for the Treatment of Nasal Polyps

Inclusion Criteria: 1. Subjects who are male or female aged 18 years or older. 2. Subjects who have signed an informed consent agreement. 3. Subjects with a history of nasal polyp symptoms during the previous 12 months. Exclusion Criteria: 1. Subjects with severe nasal polyps requiring immediate surgery. 2. Subjects presenting with unilateral polyps. 3. Subjects who have undergone surgery to treat their nasal polyps (nasal polypectomy) within one year prior to visit one. 4. Subjects who have a known fungal infection of the nose and/or paranasal sinuses, nasal candidiasis, acute or chronic infectious sinusitis of viral or bacterial nature. 5. Subjects who have had an upper respiratory tract infection within two weeks prior to Visit one or any time between Visit 1 and Visit 2. 6. Subjects having cystic fibrosis, Young's syndrome, primary ciliary dyskinesia, known HIV infection or alcohol abuse. 7. Subjects with clinically significant, uncontrolled evidence of cardiovascular, neurological, hepatic, renal, respiratory, or any other medical condition that may interfere with the study. 8. Subjects with a recent history (within six months) of a clinically significant psychiatric disorder other than mild depression. 9. Subjects who have any clinically relevant deviation from normal in the general physical examination. 10. Subjects who have received any depot, systemic or oral corticosteroid in the previous three months prior to the start of the study. 11. Subjects who are unable to cease treatment with intranasal steroids four weeks prior to Visit one. 12. Subjects with a known hypersensitivity to mint. 13. Females who are pregnant or lactating or are likely to become pregnant during the study or are less than 8 weeks postpartum. Women of childbearing age may be included if in the opinion of the investigator, they are taking adequate contraceptive measures. 14. Subjects who are unable to follow the instructions within this protocol or known inability to attend all clinic visits within the intervals stated. 15. Subjects who have participated in a clinical trial involving an investigational or marketed drug within four weeks of visit one. 16. Subjects who are allergy skin test positive to a seasonal allergen which will be present when performing the trial, that has caused, within the past 2 years, a clinically significant deterioration in nasal symptoms.